back

Canagliflozin

Subject:

  • Active Substance: Canagliflozin
  • Name: Invokana®
  • Therapeutic area: Type-2 Diabetes mellitus
  • Pharmaceutical company: Janssen-Cilag GmbH

 

Time table:

  • Publication of final assessment: 26.02.2014

 

Assessment information:

  • Title: Canagliflozin for the treatment of type 2 diabetes mellitus
  • Author/Co-Author: AAZ (Croatia), FIMEA (Finland), PRIHTA (Italy)
  • Dedicated Reviewers: CAHIAQ (Spain), HAS (France), HVB (Austria), MU Sofia (Bulgaria), MoH Czech (Czech Republic) 

› G-BA assessment available (D-101)